Interdiciplinary neurooncologcial activities and research at the Tuebinger university hospital
π§ @hih-tuebingen.bsky.social
π @unituebingen.bsky.social
π§ Website: https://www.hih-tuebingen.de/forschung/neuroonkologie
Neurooncology Tuebingen
Loading...
Great talk by @ghtabatabai.bsky.social about time management in academia
@eanoassociation.bsky.social
@eanoassociation.bsky.social
Nice opportunity to present our data on regorafenib in combination with navitoclax at @eanoassociation.bsky.social
@hannes-becker1996.bsky.social
@ghtabatabai.bsky.social
Now Daniel Merk presents his work at the DGN in Berlin.
@dgn-ev.bsky.social
@ghtabatabai.bsky.social
@hih-tuebingen.bsky.social
We are very happy to present you our work, recently accepted in Neurooncology!
@ghtabatabai.bsky.social @hih-tuebingen.bsky.social
academic.oup.com/neuro-oncolo...
Now Surender Surender on stage, presenting our data on CDK4/6 inhibition in experimental glioma!
@eanoassociation.bsky.social
@ghtabatabai.bsky.social
@hih-tuebingen.bsky.social
We are very happy to present our data at the DGN in Berlin!
@ghtabatabai.bsky.social
@hannes-becker1996.bsky.social
@dgn-ev.bsky.social
Very happy to had the opportunity to present our data at the DGN in Berlin.
@ghtabatabai.bsky.social
@hih-tuebingen.bsky.social
@dgn-ev.bsky.social
Neurooncology Tuebingen
Great poster session with nice discussions about our current work!
@eanoassociation.bsky.social
@ghtabatabai.bsky.social
@hannes-becker1996.bsky.social
@nihalolcaydogan.bsky.social
@hih-tuebingen.bsky.social
We had a wonderful #eano2025 in Prague, with multiple talks and poster presentations and fruitful discussions!
Looking forward to Rome!
@eanoassociation.bsky.social
@ghtabatabai.bsky.social
@hannes-becker1996.bsky.social
@nihalolcaydogan.bsky.social
@hih-tuebingen.bsky.social
Neurooncology Tuebingen
Neurooncology Tuebingen
Neurooncology Tuebingen
Neurooncology Tuebingen
Neurooncology Tuebingen
Neurooncology Tuebingen
Neurooncology Tuebingen
Neurooncology Tuebingen
Hannes Becker
academic.oup.com
AbstractBackground. Glioblastoma harbors frequent alterations in the retinoblastoma (RB1) pathway, providing a genetic rationale for therapeutic targeting